;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Reolysin: Completed Phase II enrollment

    Andrus Reo Ltd., Moscow, Russia Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY), Calgary, Alberta Product: Reolysin Business: Cancer Molecular target: Not applicable Description: Formulation of human reovirus type 3 …

    Published on 7/21/2014
  • Rhopressa: Phase III started

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: Rhopressa (AR-13324) Business: Ophthalmic Molecular target: Rho kinase; Norepinephrine transporter Description: Dual inhibitor of Rho kinase and the …

    Published on 7/21/2014
  • Selinexor: Phase II started

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Natick, Mass. Product: Selinexor (KPT-330) Business: Cancer Molecular target: Exportin 1 (XPO1) (CRM1) Description: Oral selective inhibitor of nuclear export (SINE) protein …

    Published on 7/21/2014
  • TKM-Ebola: Phase I hold

    Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR), Burnaby, B.C. Product: TKM-Ebola (TKM-100201) (formerly Ebola SNALP) Business: Infectious Molecular target: NA Description: Combination of short interfering RNAs (…

    Published on 7/21/2014
  • TPI 287: Phase I started

    Cortice Biosciences Inc., New York, N.Y. Product: TPI 287 Business: Neurology Molecular target: Not available Description: Third-generation taxane Indication: Treat progressive supranuclear palsy (PSP) and corticobasal …

    Published on 7/21/2014
  • XEN-D0501: Phase IIa started

    Ario Pharma Ltd., Cambridge, U.K. Product: XEN-D0501 Business: Pulmonary Molecular target: Transient receptor potential vanilloid 1 (TRPV1) (VR1) Description: Transient receptor potential vanilloid 1 (TRPV1; VR1) …

    Published on 7/21/2014
  • Zeneo Methotrexate: Clinical trial started

    Crossject S.A. (Euronext:ALCJ), Chenove, France Product: Zeneo Methotrexate Business: Autoimmune Molecular target: NA Description: Methotrexate delivered using the companys Zeneo needle-free injection system Indication:…

    Published on 7/21/2014
  • ZS-9: Completed Phase III enrollment

    ZS Pharma Inc. (NASDAQ:ZSPH), Coppell, Texas Product: ZS-9 Business: Hematology Molecular target: NA Description: Inorganic crystal form of zirconium silicate designed to trap potassium ions over other ions throughout …

    Published on 7/21/2014
  • Allob: Phase I/IIa started

    Bone Therapeutics S.A., Gosselies, Belgium Product: Allob Business: Musculoskeletal Molecular target: NA Description: Allogeneic osteoblastic cell therapy Indication: Treat delayed-union fractures Endpoint: Percentage …

    Published on 7/14/2014
  • Ampion: Phase I/II started

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Greenwood Village, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide …

    Published on 7/14/2014
  • BAL30072: Phase I started

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Product: BAL30072 Business: Infectious Molecular target: NA Description: Siderophore sulfactam antibiotic Indication: Treat Gram-negative bacterial infection …

    Published on 7/14/2014
  • Bardoxolone methyl: Phase II started

    Reata Pharmaceuticals Inc., Irving, Texas AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Bardoxolone methyl (formerly RTA 402) Business: Cardiovascular Molecular …

    Published on 7/14/2014
  • BeiGene-290: Phase I started

    BeiGene Co. Ltd., Beijing, China Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: BeiGene-290, BGB-290 Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: Poly(ADP-ribose) polymerase (…

    Published on 7/14/2014
  • Brilacidin: Phase IIb ongoing

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin (formerly PMX-30063) Business: Infectious Molecular target: NA Description: Synthetic defensin mimetic bactericidal antibiotic Indication: Treat acute …

    Published on 7/14/2014
  • CHS-0214: Phase III started

    Coherus BioSciences Inc., Redwood City, Calif. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: CHS-0214 Business: Autoimmune Molecular target: Tumor …

    Published on 7/14/2014
  • CMX-2043: Phase IIa started

    Ischemix Inc., Maynard, Mass. Product: CMX-2043 Business: Cardiovascular Molecular target: Protein kinase B (PKB) (PKBA) (AKT) (AKT1) Description: Small molecule that modulates the protein kinase B (PKB; PKBA; AKT; AKT1…

    Published on 7/14/2014
  • CO-1686: Phase II started

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Product: CO-1686, AVL-301 Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) Description: Small …

    Published on 7/14/2014
  • Diazoxide choline controlled release: Phase I started

    Essentialis Inc., Carlsbad, Calif. Product: Diazoxide choline controlled release (DCCR) Business: Endocrine/Metabolic Molecular target: ATP-dependent potassium channel (KATP) Description: ATP-dependent potassium channel…

    Published on 7/14/2014
  • Eltrombopag: Phase III started

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Eltrombopag (Promacta, Revolade) Business: Cancer Molecular target: Thrombopoietin (TPO) …

    Published on 7/14/2014
  • Eye-D insert: Phase I/IIa started

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: Eye-D insert Business: Ophthalmic Molecular target: NA Description: Intraocular controlled-release insert containing latanoprost, a prostaglandin …

    Published on 7/14/2014
  • FBP vaccine: Completed Phase IIa enrollment

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Product: FBP vaccine (GALE-301) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP) vaccine Indication: …

    Published on 7/14/2014
  • GFT505: Phase IIb ongoing

    Genfit S.A. (Euronext:GNFT), Loos, France Product: GFT505 Business: Hepatic Molecular target: Peroxisome proliferation activated receptor (PPAR) Description: Dual peroxisome proliferation activated receptor (PPAR) alpha…

    Published on 7/14/2014
  • GLPG1690: Phase I started

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: GLPG1690 Business: Pulmonary Molecular target: NA Description: Undisclosed compound Indication: …

    Published on 7/14/2014
  • Glycoconjugate ExPEC vaccine: Phase I started

    GlycoVaxyn AG, Schlieren, Switzerland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Glycoconjugate ExPEC vaccine Business: Infectious Molecular target: NA Description: Bioconjugate vaccine against extra-…

    Published on 7/14/2014
  • ItMSCs: Phase IIa started

    Stemedica Cell Technologies Inc., San Diego, Calif. Product: ItMSCs Business: Cardiovascular Molecular target: NA Description: Transplanted ischemic-tolerant mesenchymal stem cells Indication: Treat chronic heart …

    Published on 7/14/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993